Member Posts > Cardiol Therapeutics Advances Next-Gen Heart Failure Therapy with Cannabidiol Research
A newly published study in JACC: Basic to Translational Science provides compelling evidence that cannabidiol (CBD) may revolutionize heart failure treatment. Conducted by leading researchers from Tecnológico de Monterrey and the DeBakey Heart and Vascular Center, the study shows that CBD helps prevent cardiac dysfunction and remodeling by protecting mitochondrial function and calcium handling.
How CRD-38 is Changing Heart Failure Treatment
• Targets heart failure with preserved ejection fraction (HFpEF), a condition with limited treatment options.
• Prevents fibrosis and inflammation, major contributors to disease progression.
• Enhances mitochondrial function, crucial for maintaining heart cell energy production.
Dr. Andrew Hamer, Chief Medical Officer at Cardiol, emphasized that this breakthrough supports CRD-38's development as a next-generation therapy for heart failure patients.

#CardiolTherapeutics #InvestorRelations #StockMarket #HealthcareInvestments #BiotechStocks #Pharmaceuticals #CardiacCare #FinancialUpdates #HeartHealth #MedicalInnovation #Pericarditis #HealthcareResearch #AdvancedTherapies #CardiolRx #CRD38 #Myocarditis